AngioDynamics (NASDAQ:ANGO) Shares Unloaded Rep. Debbie Wasserman Schultz

Representative Debbie Wasserman Schultz (D-Florida) recently sold shares of AngioDynamics, Inc. NASDAQ: ANGO. In a filing disclosed on October 24th, the Representative disclosed that they had sold between $1,001 and $15,000 in AngioDynamics stock on October 20th.

Representative Debbie Wasserman Schultz also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Controladora Vuela Compania de Aviacion NYSE: VLRS on 9/29/2025.
• Sold $1,001 - $15,000 in shares of Berry NASDAQ: BRY on 9/15/2025.
• Purchased $1,001 - $15,000 in shares of Stratasys NASDAQ: SSYS on 8/15/2025.
• Purchased $1,001 - $15,000 in shares of Ichor NASDAQ: ICHR on 8/5/2025.

AngioDynamics Trading Down 0.4%

AngioDynamics stock opened at $12.29 on Tuesday. The firm's 50 day simple moving average is $10.85 and its 200 day simple moving average is $9.97. The firm has a market capitalization of $506.35 million, a PE ratio of -15.76 and a beta of 0.78. AngioDynamics, Inc. has a 1-year low of $6.57 and a 1-year high of $13.50.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last posted its earnings results on Thursday, October 2nd. The medical instruments supplier reported ($0.10) earnings per share for the quarter, topping analysts' consensus estimates of ($0.12) by $0.02. The business had revenue of $75.71 million for the quarter, compared to analyst estimates of $72.69 million. AngioDynamics had a negative net margin of 10.67% and a negative return on equity of 3.16%. AngioDynamics's revenue was up 12.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.11) EPS. AngioDynamics has set its FY 2026 guidance at -0.330--0.230 EPS. Research analysts forecast that AngioDynamics, Inc. will post -0.37 earnings per share for the current year.

Insider Transactions at AngioDynamics

In other news, CEO James C. Clemmer purchased 10,000 shares of the company's stock in a transaction that occurred on Thursday, October 9th. The shares were bought at an average price of $11.15 per share, for a total transaction of $111,500.00. Following the purchase, the chief executive officer directly owned 882,529 shares in the company, valued at approximately $9,840,198.35. This trade represents a 1.15% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Lawrence T. Weiss purchased 10,000 shares of the company's stock in a transaction that occurred on Tuesday, October 21st. The stock was purchased at an average price of $11.81 per share, for a total transaction of $118,100.00. Following the purchase, the senior vice president owned 93,597 shares in the company, valued at $1,105,380.57. This represents a 11.96% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 20,890 shares of company stock worth $239,532. 6.00% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of research firms recently weighed in on ANGO. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of AngioDynamics in a report on Wednesday, October 8th. Lake Street Capital began coverage on shares of AngioDynamics in a report on Wednesday, July 16th. They issued a "buy" rating and a $24.00 price target on the stock. Canaccord Genuity Group increased their price target on shares of AngioDynamics from $17.00 to $18.00 and gave the stock a "buy" rating in a report on Friday, October 3rd. HC Wainwright reissued a "buy" rating and issued a $16.00 price target on shares of AngioDynamics in a report on Wednesday, July 16th. Finally, Wall Street Zen lowered shares of AngioDynamics from a "buy" rating to a "hold" rating in a report on Saturday, October 4th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, AngioDynamics presently has a consensus rating of "Moderate Buy" and an average price target of $19.33.

Get Our Latest Report on ANGO

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Divisadero Street Capital Management LP lifted its stake in shares of AngioDynamics by 253.7% in the 2nd quarter. Divisadero Street Capital Management LP now owns 3,395,430 shares of the medical instruments supplier's stock valued at $33,683,000 after acquiring an additional 2,435,365 shares during the last quarter. Armistice Capital LLC increased its position in AngioDynamics by 140.1% during the 1st quarter. Armistice Capital LLC now owns 2,094,000 shares of the medical instruments supplier's stock valued at $19,663,000 after purchasing an additional 1,222,000 shares during the period. Nuveen LLC purchased a new position in AngioDynamics during the 1st quarter valued at $10,803,000. Bastion Asset Management Inc. purchased a new stake in shares of AngioDynamics in the 1st quarter worth about $6,601,000. Finally, AIGH Capital Management LLC purchased a new stake in shares of AngioDynamics in the 1st quarter worth about $4,455,000. Hedge funds and other institutional investors own 89.43% of the company's stock.

About Representative Wasserman Schultz

Debbie Wasserman Schultz (Democratic Party) is a member of the U.S. House, representing Florida's 25th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027. Wasserman Schultz (Democratic Party) is running for re-election to the U.S. House to represent Florida's 25th Congressional District. She declared candidacy for the 2026 election. Debbie Wasserman Schultz was born in Forest Hills, New York. Wasserman Schultz graduated from Half Hollow Hills High School East in 1984. She earned a B.A. and M.A. from the University of Florida in 1988 and 1990, respectively. Wasserman Schultz's career experience includes working as a staffer to former U.S. Representative Peter Deutsch.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.

Read More

• Five stocks we like better than AngioDynamics
• How to Effectively Use the MarketBeat Ratings Screener
• Growth Picks: 3 Low-Cost Stocks That Could Double in Value
• Best Energy Stocks - Energy Stocks to Buy Now
• Are These 3 Beaten-Down Stocks Ready to Rebound?
• 3 Monster Growth Stocks to Buy Now
• Does the Trump-Induced Quantum Stock Rally Have Legs?

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in AngioDynamics Right Now?

Before you consider AngioDynamics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AngioDynamics wasn't on the list.

While AngioDynamics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here